Drug intelligence / Profile preview

cyclosporine (Apidel)

Development stage
Preclinical
Lead developer
Novartis
Modality
Small Molecules, Nanoparticles → Drug Delivery Systems
Administration
Topical, Ophthalmic
01

Overview

Cyclosporine (also known as ciclosporin) is a small molecule immunosuppressant that functions as a calcineurin inhibitor. This specific formulation, developed by Apidel, utilizes the proprietary APID-SOL polymeric micelle delivery system to enhance the solubility and bioavailability of the hydrophobic cyclosporine molecule. By encapsulating the drug within polymeric micelles, the formulation is designed to improve therapeutic delivery for inflammatory conditions of the eye and skin, including dry eye syndrome, uveitis, corneal graft rejection, and psoriasis. The APID-SOL technology aims to provide a clear, aqueous solution that avoids the irritation often associated with traditional oil-based cyclosporine formulations. As of the last available reports, the candidate was in preclinical development.

Other names
Cyclosporine A polymeric micelle formulationAPID-SOL cyclosporine
02

Targets

CN (Calcineurin)PPIA (Peptidyl-prolyl cis-trans isomerase A)ABCB1 (P-glycoprotein)

Beyond the preview

Go deeper on cyclosporine (Apidel).

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

  • Trial phase
  • Status
  • Readouts

Indications & development

Explore development by indication, patient population, and geography.

  • Indications
  • Development status
  • Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

  • Partners
  • Deal terms
  • Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

  • Patents
  • Expiration dates
  • Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

  • Competing assets
  • Targets
  • Development stage

Research & analysis

Connect source evidence and development news to your research questions.

  • Publications
  • News
  • Analysis

Bring the full picture into focus.

See how Gosset can support your research on cyclosporine (Apidel).

Gosset Free

Get started with Gosset.

Enter your corporate email.

Work email preferred.

Book a call